Building on these findings, several studies have utilized S1R ligands to enhance the targeting and delivery of therapeutic nanoparticles to tumors, successfully improving drug delivery in models of melanoma, prostate, lung, and breast cancers [39,40]. This evidence concerns the gene TMBIM4 and breast carcinoma.